|
Genetic Mapping of Atherogenic Lipoprotein Phenotypes Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Genetic Mapping of Atherogenic Lipoprotein Phenotypes conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Genetic Mapping of Atherogenic Lipoprotein Phenotypes Clinical research trials and Genetic Mapping of Atherogenic Lipoprotein Phenotypes healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Genetic Mapping of Atherogenic Lipoprotein Phenotypes. Genetic Mapping of Atherogenic Lipoprotein Phenotypes Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Genetic Mapping of Atherogenic Lipoprotein Phenotypes clinical trial. Human subjects often obtain the finest healthcare possible for their Genetic Mapping of Atherogenic Lipoprotein Phenotypes condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Genetic Mapping of Atherogenic Lipoprotein Phenotypes  Genetic Mapping of Atherogenic Lipoprotein Phenotypes
Genetic Mapping of Atherogenic Lipoprotein Phenotypes
For Condition: Heart Diseases,Atherosclerosis,Cardiovascular Diseases
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To map the major gene influencing low-density lipoprotein subclass phenotypes, denoted atherogenic lipoprotein (ALP) phenotypes, with a long term goal of cloning the ALP gene and understanding its role in genetic susceptibility to atherosclerosis.
Details: BACKGROUND: ALP phenotype B (ALP-B), characterized by a predominance of small, dense LDL particles as determined by gradient gel electrophoresis, has been associated with increased risk of myocardial infarction and a constellation of atherogenic lipid and apolipoprotein (apo) changes. Based on complex segregation analysis, ALP-B appeared to be influenced by a single major genetic locus with a dominant mode of inheritance and a common allele frequency. This project was designed to identify a new gene involved in susceptibility to coronary heart disease. DESIGN NARRATIVE: The investigators identified, collected and constructed a repository of immortalized cell lines and lipid and apo measurements from members of families informative for ALP. They tested genes implicated in lipoprotein metabolism as possible candidate ALP genes and used highly informative DNA probes to search the genome for linkage to the ALP gene. They also refined the model for the inheritance of ALP phenotypes and tested for genetic-environmental interactions. Forty informative families were recruited for the repository. The families were identified through two sources of probands: former participants in a cholesterol-lowering diet study and patients seen at the lipid clinics at the University of Washington. Each participating family member completed a medical history questionnaire and provided a blood sample for ALP phenotype determination, for DNA studies, and for lipid and apo measurements. Linkage studies and LOD score analyses began with a candidate gene approach, and continued by using DNA probes that revealed restriction fragment length polymorphisms (RFLPs) to search the genome for linkage to the ALP gene. When a linkage was found, ALP genotype information was used to refine the statistical model describing the inheritance of ALP phenotypes, and to evaluate genetic-environmental interactions involving lipid and apo levels and environmental and behavioral factors.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Male
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: 4909;
Study Start Date: August 1991
Record last reviewed: May 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005465
Other Atherosclerosis Studies:
1. Public Access Defibrillation (PAD) Community Trial
2. Polyunsaturates and KCL to Control Mild Hypertension
3. Trial of Activity for Adolescent Girls (TAAG)
4. Prevention of Early Readmission in Elderly Congestive Heart Failure Patients
5. Sleep Heart Health Study (SHHS)
Related Studies:
Other Atherosclerosis Clinical Trials
Other Clinical Trials
Other Clinical Trials
Genetic Mapping of Atherogenic Lipoprotein Phenotypes
|
|
|
|
|
|
|
|
